By vgreene, 22 April, 2016 Labs: ✓ baseline fasting lipid panel,2 ✓ ALT, and if indicated ✓ CK. Eval/treat TG ≥500 mg/dL, unexplained ALT >3x ULN. Consider eval for secondary causes/conditions that may influence statin safety. If LDL–C ≥190 mg/dL,3 strongly consider lipid specialis
By vgreene, 22 April, 2016 Daily statin dose:1 Atorvastatin 10 mg, fluvastatin 80 mg (as 40 mg bid), lovastatin 40 mg, pravastatin 40 mg, rosuvastatin 10 mg, simvastatin 20-40 mg
By vgreene, 22 April, 2016 Repeat fasting lipid panel4 4-12wk after statin start (or modification), then q3-12mo
By vgreene, 22 April, 2016 If LDL–C reduction from baseline6 ≥50% (may consider absolute LDL–C # depending on comorbidities):7 Continue monitoring
By vgreene, 22 April, 2016 Labs: ✓ baseline fasting lipid panel,4 ✓ ALT, and if indicated ✓ CK. Eval/treat TG ≥500 mg/dL, unexplained ALT >3x ULN. Consider eval for secondary causes/conditions that may influence statin safety. If LDL–C ≥190 mg/dL,5 strongly consider lipid specialis
By vgreene, 22 April, 2016 Stone NJ, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the ACC/AHA Task Force on Practice Guidelines. <i>Circulation.</i> 2014;129(25 Suppl 2):S1-45.
